Covance Appoints VP of Clinical Development Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Covance Appoints VP of Clinical Development Services



Covance reported that Barry J. Goldstein, MD, PhD, has joined its clinical development services business as vice-president and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine, and renal unit.  In this new role, Goldstein will join the medical & scientific affairs leadership team and will be based in Princeton, NJ.
 
Goldstein joins Covance from Merck where he served as vice-president in clinical research and therapeutic area head for diabetes and endocrinology, since 2008.  In this role, he managed Merck’s Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women’s health.  His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies. In addition to his biopharmaceutical industry experience, Goldstein’s medical career includes serving as director, division of endocrinology, diabetes & metabolic diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008.  His most recent academic roles include professor of medicine, biochemistry and molecular pharmacology at Jefferson from 1997 to 2008.
 
Source: Covance

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here